Claims for Patent: 11,007,139

Summary for Patent: 11,007,139

Title:	Risperidone or paliperidone implant formulation
Abstract:	The present invention is directed to an injectable intramuscular depot composition suitable for forming an in situ solid implant in a body, comprising a drug which is risperidone and/or paliperidone or any pharmaceutically acceptable salt thereof in any combination, a biocompatible copolymer based on lactic and glycolic acid having a monomer ratio of lactic to glycolic acid of about 50:50 and DMSO solvent, wherein the composition releases the drug with an immediate onset of action and continuously for at least 4 weeks and wherein the composition has a pharmacokinetic profile in vivo that makes it suitable to be administered each 4 weeks or even longer periods.
Inventor(s):	Gutierro Aduriz Ibon, Franco Rodriguez Guillermo
Assignee:	Laboratorios Farmacéuticos ROVI, S.A.
Application Number:	US16456900
Patent Claims:	1. A method of treating schizophrenia or bipolar disorder , the method comprising administering a therapeutically effective amount of an injectable depot composition to a subject in need thereof , said injectable composition consisting ofabout 13% wt of drug which is risperidone and/or paliperidone or any pharmaceutically acceptable salt thereof in any combination; anda polymeric solution consisting of DMSO and biocompatible poly(lactide-co-glycolide) (PLGA) copolymer having a monomer ratio of lactic acid to glycolic acid of about 50:50 and an inherent viscosity in the range of 0.25-0.30 dl/g measured by gel permeation chromatography in tetrahydrofuran at 30° C. using a flow rate of 1 ml/min; whereinthe mass ratio of polymeric solution to drug is about 6.5:1 to about 7:1; andthe mass ratio of DMSO to drug is about 4:1 to about 5:1.2. The method of claim 1 , wherein said injectable composition is administered intramuscularly claim 1 , intraperitoneally claim 1 , intrathecally claim 1 , intravaginally claim 1 , subcutaneously claim 1 , intracranially or intracerebrally.3. The method of claim 1 , wherein said injectable composition is administered every two weeks claim 1 , every three weeks claim 1 , every four weeks claim 1 , or every five weeks during a treatment period.4. The method of claim 1 , wherein said injectable composition comprises about 25 mg to about 150 mg of said drug.5. The method of claim 1 , wherein after administration said injectable composition:a) provides an average plasma concentration of said drug that ranges from about 5 to about 80 ng/ml when about 116 to about 700 mg, respectively, of said injectable composition comprising about 25 mg to about 150 mg, respectively, of said drug are administered;b) provides an average plasma concentration of said drug that ranges from about 5 to about 150 ng/ml or from about 10 to about 100 ng/ml in the steady state during a dosing period;c) provides an average Cmin of said drug in the range of about 1-80 ng/ml, 5-50 ng/ml, or about 5-40 ng/ml when an amount of said injectable composition equivalent to a dose of about 25-150 mg, about 37.5-125 mg, or about 50-100 mg, respectively, of said drug is administered;d) provides an average Cmax of said drug in the range of about 8-300 ng/ml, 10-150 ng/ml, or 10-120 ng/ml when an amount of said injectable composition equivalent to a dose of 25-150 mg, 37.5-125 mg, or 50-100 mg, respectively, of said drug is administered; ore) provides therapeutic plasma levels of said drug from the first day to at least 14 days, at least 21 days, at least 28 days, at least 31 days, or at least 36 days after administration.6. The method of claim 1 , wherein said compositiona) provides a plasma concentration profile of said drug that exhibits one, two or more maxima;b) provides a plasma concentration profile of said drug that exhibits one, two or more minima;c) provides a plasma concentration profile of said drug that exhibits a maximum during the initial one to six days, one to three days, or one to two days after administration;d) provides a plasma concentration profile of said drug that exhibits a maximum during 11 to 13 days or 12 to 14 days after administration;e) provides a plasma concentration profile of said drug that exhibits a maximum during 14 to 24 days of a 4-week dosing period; orf) provides a plasma concentration profile of said drug that is within ±20% of the average or mean plasma concentration during a dosing period.7. The method of claim 1 , wherein plural doses of said injectable composition are administered.8. The method of further comprising sterilizing said copolymer claim 1 , said polymeric solution and/or said risperidone or paliperidone prior to administration.9. The method of claim 8 , wherein said sterilizing comprises exposure to a dose of beta-irradiation in the range of 5-25 KGy; or wherein said sterilizing comprises filtering said polymeric solution.10. The method of claim 1 , wherein said injectable composition releases 0.5% wt up to 20% wt of its charge of risperidone or paliperidone within 24 hours after being placed in an aqueous environment.11. The method of claim 1 , wherein the drug has a particle size distribution selected from the group consisting ofa) not more than 10% of the total volume of the particles are smaller than 10 microns, and not more than 10% of the total volume of particles are greater than 225 microns;b) not more than 10% of the total volume of the particles is less than the range 1-10 μm, not more than 10% of the total volume of particles is greater than the range 225-400 μm, and the d0.5 of the size distribution is in the range of about 40-200 μm;c) expressed as volume, d0.9 is about 150 to about 400 μm, d0.5 is about 40 to about 200 μm and d0.1 is about 10 to about 60 μm;d) not more than 10% of the total volume of the particles is less than the range 0.1-10 μm, not more than the 10% of the total volume of particles is greater than the range 225-1000 μm, and the d0.5 of the size distribution is in the range of about 10-1000 μm;e) not more than 10% of the total volume of the particles is less than the range 0.5-10 μm, not more than the 10% of the total volume of particles is greater than the range 225-700 μm, and the d0.5 of the size distribution is in the range of about 20-700 μm;f) not more than 10% of the total volume of the particles is less than the range 1-10 μm, not more than the 10% of the total volume of particles is greater than the range 225-400 μm, and the d0.5 of the size distribution is in the range of about 40-200 μm;g) d0.1 of 27.49 microns, d0.5 of 79.9 microns, and d0.9 of 176.66 microns;h) d0.1 of 17.41 microns, d0.5 of 51.61 microns, and d0.9 of 175.32 microns; andi) d0.1 of ≤10 microns, d0.5 of 40-130 microns, and d0.9 of >225 microns.12. The method of claim 1 , wherein said monomer ratio ranges from 48:52 to 52:48.13. A method of treating schizophrenia or bipolar disorder claim 1 , the method comprising administering a therapeutically effective amount of an injectable depot composition to a subject in need thereof claim 1 , said injectable composition consisting of about 13% wt of drug which is risperidone and/or paliperidone or any pharmaceutically acceptable salt thereof in any combination;DMSO; andbiocompatible poly(lactide-co-glycolide) (PLGA) copolymer having a monomer ratio of lactic acid to glycolic acid of about 50:50 and an inherent viscosity in the range of 0.25-0.29 dl/g measured by gel permeation chromatography in tetrahydrofuran at 30° C. using a flow rate of 1 ml/min; whereinthe mass ratio of drug to (polymer+drug) is about 33%, expressed as the percentage of the drug weight with respect to total weight of the drug plus polymer; andthe mass ratio of DMSO to drug is about 4.66:1.14. The method of claim 13 , wherein said injectable composition is administered intramuscularly claim 13 , intraperitoneally claim 13 , intrathecally claim 13 , intravaginally claim 13 , subcutaneously claim 13 , intracranially or intracerebrally.15. The method of claim 13 , wherein said injectable composition is administered every two weeks claim 13 , every three weeks claim 13 , every four weeks claim 13 , or every five weeks during a treatment period.16. The method of claim 13 , wherein said injectable composition comprises about 25 mg to about 150 mg of said drug.17. The method of claim 13 , wherein after administration said injectable composition:a) provides an average plasma concentration of said drug that ranges from about 5 to about 80 ng/ml when about 116 to about 700 mg, respectively, of said injectable composition comprising about 25 mg to about 150 mg, respectively, of said drug are administered;b) provides an average plasma concentration of said drug that ranges from about 5 to about 150 ng/ml or from about 10 to about 100 ng/ml in the steady state during a dosing period;c) provides an average Cmin of said drug in the range of about 1-80 ng/ml, 5-50 ng/ml, or about 5-40 ng/ml when an amount of said injectable composition equivalent to a dose of about 25-150 mg, about 37.5-125 mg, or about 50-100 mg, respectively, of said drug is administered;d) provides an average Cmax of said drug in the range of about 8-300 ng/ml, 10-150 ng/ml, or 10-120 ng/ml when an amount of said injectable composition equivalent to a dose of 25-150 mg, 37.5-125 mg, or 50-100 mg, respectively, of said drug is administered; ore) provides therapeutic plasma levels of said drug from the first day to at least 14 days, at least 21 days, at least 28 days, at least 31 days, or at least 36 days after administration.18. The method of claim 13 , wherein said compositiona) provides a plasma concentration profile of said drug that exhibits one, two or more maxima;b) provides a plasma concentration profile of said drug that exhibits one, two or more minima;c) provides a plasma concentration profile of said drug that exhibits a maximum during the initial one to six days, one to three days, or one to two days after administration;d) provides a plasma concentration profile of said drug that exhibits a maximum during 11 to 13 days or 12 to 14 days after administration;e) provides a plasma concentration profile of said drug that exhibits a maximum during 14 to 24 days of a 4-week dosing period; orf) provides a plasma concentration profile of said drug that is within ±20% of the average or mean plasma concentration during a dosing period.19. The method of claim 13 , wherein plural doses of said injectable composition are administered.20. The method of further comprising sterilizing said copolymer claim 13 , said polymeric solution and/or said risperidone or paliperidone prior to administration.21. The method of claim 20 , wherein said sterilizing comprises exposure to a dose of beta-irradiation in the range of 5-25 KGy; or wherein said sterilizing comprises filtering said polymeric solution.22. The method of claim 13 , wherein said injectable composition releases 0.5% wt up to 20% wt of its charge of risperidone or paliperidone within 24 hours after being placed in an aqueous environment.23. The method of claim 13 , wherein the drug has a particle size distribution selected from the group consisting ofa) not more than 10% of the total volume of the particles are smaller than 10 microns, and not more than 10% of the total volume of particles are greater than 225 microns;b) not more than 10% of the total volume of the particles is less than the range 1-10 μm, not more than 10% of the total volume of particles is greater than the range 225-400 μm, and the d0.5 of the size distribution is in the range of about 40-200 μm;c) expressed as volume, d0.9 is about 150 to about 400 μm, d0.5 is about 40 to about 200 μm and d0.1 is about 10 to about 60 μm;d) not more than 10% of the total volume of the particles is less than the range 0.1-10 μm, not more than 10% of the total volume of particles is greater than the range 225-1000 μm, and the d0.5 of the size distribution is in the range of about 10-1000 μm;e) not more than 10% of the total volume of the particles is less than the range 0.5-10 μm, not more than 10% of the total volume of particles is greater than the range 225-700 μm, and the d0.5 of the size distribution is in the range of about 20-700 μm;f) not more than 10% of the total volume of the particles is less than the range 1-10 μm, not more than 10% of the total volume of particles is greater than the range 225-400 μm, and the d0.5 of the size distribution is in the range of about 40-200 μm;g) d0.1 of 27.49 microns, d0.5 of 79.9 microns, and d0.9 of 176.66 microns;h) d0.1 of 17.41 microns, d0.5 of 51.61 microns, and d0.9 of 175.32 microns; andi) d0.1 of ≤10 microns, d0.5 of 40-130 microns, and d0.9 of >225 microns.24. The method of claim 13 , wherein said monomer ratio ranges from 48:52 to 52:48.25. A method of treating schizophrenia or bipolar disorder claim 13 , the method comprising administering a therapeutically effective amount of an injectable depot composition to a subject in need thereof claim 13 , said injectable composition consisting ofabout 13% wt of drug which is risperidone and/or paliperidone or any pharmaceutically acceptable salt thereof in any combination;DMSO; and25-27% wt of biocompatible poly(lactide-co-glycolide) (PLGA) copolymer having a monomer ratio of lactic acid to glycolic acid of about 50:50 and an inherent viscosity in the range of 0.25-0.30 dl/g measured by gel permeation chromatography in tetrahydrofuran at 30° C. using a flow rate of 1 ml/min; whereinthe mass ratio of DMSO to drug is about 4:1 to about 5:1.26. The method of claim 25 , wherein said injectable composition is administered intramuscularly claim 25 , intraperitoneally claim 25 , intrathecally claim 25 , intravaginally claim 25 , subcutaneously claim 25 , intracranially or intracerebrally.27. The method of claim 25 , wherein said injectable composition is administered every two weeks claim 25 , every three weeks claim 25 , every four weeks claim 25 , or every five weeks during a treatment period.28. The method of claim 25 , wherein said injectable composition comprises about 25 mg to about 150 mg of said drug.29. The method of claim 25 , wherein after administration said injectable compositiona) provides an average plasma concentration of said drug that ranges from about 5 to about 80 ng/ml when about 116 to about 700 mg, respectively, of said injectable composition comprising about 25 mg to about 150 mg, respectively, of said drug are administered;b) provides an average plasma concentration of said drug that ranges from about 5 to about 150 ng/ml or from about 10 to about 100 ng/ml in the steady state during a dosing period;c) provides an average Cmin of said drug in the range of about 1-80 ng/ml, 5-50 ng/ml, or about 5-40 ng/ml when an amount of said injectable composition equivalent to a dose of about 25-150 mg, about 37.5-125 mg, or about 50-100 mg, respectively, of said drug is administered;d) provides an average Cmax of said drug in the range of about 8-300 ng/ml, 10-150 ng/ml, or 10-120 ng/ml when an amount of said injectable composition equivalent to a dose of 25-150 mg, 37.5-125 mg, or 50-100 mg, respectively, of said drug is administered; ore) provides therapeutic plasma levels of said drug from the first day to at least 14 days, at least 21 days, at least 28 days, at least 31 days, or at least 36 days after administration.30. The method of claim 25 , wherein said injectable compositiona) provides a plasma concentration profile of said drug that exhibits one, two or more maxima;b) provides a plasma concentration profile of said drug that exhibits one, two or more minima;c) provides a plasma concentration profile of said drug that exhibits a maximum during the initial one to six days, one to three days, or one to two days after administration;d) provides a plasma concentration profile of said drug that exhibits a maximum during 11 to 13 days or 12 to 14 days after administration;e) provides a plasma concentration profile of said drug that exhibits a maximum during 14 to 24 days of a 4-week dosing period; orf) provides a plasma concentration profile of said drug that is within ±20% of the average or mean plasma concentration during a dosing period.31. The method of claim 25 , wherein plural doses of said injectable composition are administered.32. The method of further comprising sterilizing said copolymer claim 25 , said polymeric solution and/or said risperidone or paliperidone prior to administration.33. The method of claim 32 , wherein said sterilizing comprises exposure to a dose of beta-irradiation in the range of 5-25 KGy; or wherein said sterilizing comprises filtering said polymeric solution.34. The method of claim 25 , wherein said injectable composition releases 0.5% wt up to 20% wt of its charge of risperidone or paliperidone within 24 hours after being placed in an aqueous environment.35. The method of claim 25 , wherein the drug has a particle size distribution selected from the group consisting ofa) not more than 10% of the total volume of the particles are smaller than 10 microns, and not more than 10% of the total volume of particles are greater than 225 microns;b) not more than 10% of the total volume of the particles is less than the range 1-10 μm, not more than 10% of the total volume of particles is greater than the range 225-400 μm, and the d0.5 of the size distribution is in the range of about 40-200 μm;c) expressed as volume, d0.9 is about 150 to about 400 μm, d0.5 is about 40 to about 200 μm and d0.1 is about 10 to about 60 μm;d) not more than 10% of the total volume of the particles is less than the range 0.1-10 μm, not more than 10% of the total volume of particles is greater than the range 225-1000 μm, and the d0.5 of the size distribution is in the range of about 10-1000 μm;e) not more than 10% of the total volume of the particles is less than the range 0.5-10 μm, not more than 10% of the total volume of particles is greater than the range 225-700 μm, and the d0.5 of the size distribution is in the range of about 20-700 μm;f) not more than 10% of the total volume of the particles is less than the range 1-10 μm, not more than 10% of the total volume of particles is greater than the range 225-400 μm, and the d0.5 of the size distribution is in the range of about 40-200 μm;g) d0.1 of 27.49 microns, d0.5 of 79.9 microns, and d0.9 of 176.66 microns;h) d0.1 of 17.41 microns, d0.5 of 51.61 microns, and d0.9 of 175.32 microns; andi) d0.1 of ≤10 microns, d0.5 of 40-130 microns, and d0.9 of >225 microns.36. The method of claim 25 , wherein said monomer ratio ranges from 48:52 to 52:48.37. A method of treating schizophrenia or bipolar disorder claim 25 , the method comprising administering a therapeutically effective amount of an injectable depot composition to a subject in need thereof claim 25 , said subject an injectable composition consisting of about 13% wt of drug which is risperidone and/or paliperidone or any pharmaceutically acceptable salt thereof in any combination;DMSO; and25-27% wt of biocompatible poly(lactide-co-glycolide) (PLGA) copolymer having a monomer ratio of lactic acid to glycolic acid of about 50:50 and a molecular weight in the range of 28-43 kDa; whereinthe mass ratio of DMSO to drug is about 4:1 to about 5:1.38. The method of claim 37 , wherein said copolymer has molecular weight in the range of 30-36 kDa.39. The method of claim 37 , wherein said injectable composition is administered intramuscularly claim 37 , intraperitoneally claim 37 , intrathecally claim 37 , intravaginally claim 37 , subcutaneously claim 37 , intracranially or intracerebrally.40. The method of claim 37 , wherein said injectable composition is administered every two weeks claim 37 , every three weeks claim 37 , every four weeks claim 37 , or every five weeks during a treatment period.41. The method of claim 37 , wherein said injectable composition comprises about 25 mg to about 150 mg of said drug.42. The method of claim 37 , wherein after administration said injectable composition:a) provides an average plasma concentration of said drug that ranges from about 5 to about 80 ng/ml when about 116 to about 700 mg, respectively, of said injectable composition comprising about 25 mg to about 150 mg, respectively, of said drug are administered;b) provides an average plasma concentration of said drug that ranges from about 5 to about 150 ng/ml or from about 10 to about 100 ng/ml in the steady state during a dosing period;c) provides an average Cmin of said drug in the range of about 1-80 ng/ml, 5-50 ng/ml, or about 5-40 ng/ml when an amount of said injectable composition equivalent to a dose of about 25-150 mg, about 37.5-125 mg, or about 50-100 mg, respectively, of said drug is administered;d) provides an average Cmax of said drug in the range of about 8-300 ng/ml, 10-150 ng/ml, or 10-120 ng/ml when an amount of said injectable composition equivalent to a dose of 25-150 mg, 37.5-125 mg, or 50-100 mg, respectively, of said drug is administered; ore) provides therapeutic plasma levels of said drug from the first day to at least 14 days, at least 21 days, at least 28 days, at least 31 days, or at least 36 days after administration.43. The method of claim 37 , wherein said injectable compositiona) provides a plasma concentration profile of said drug that exhibits one, two or more maxima;b) provides a plasma concentration profile of said drug that exhibits one, two or more minima;c) provides a plasma concentration profile of said drug that exhibits a maximum during the initial one to six days, one to three days, or one to two days after administration;d) provides a plasma concentration profile of said drug that exhibits a maximum during 11 to 13 days or 12 to 14 days after administration;e) provides a plasma concentration profile of said drug that exhibits a maximum during 14 to 24 days of a 4-week dosing period; orf) provides a plasma concentration profile of said drug that is within ±20% of the average or mean plasma concentration during a dosing period.44. The method of claim 37 , wherein plural doses of said injectable composition are administered.45. The method of further comprising sterilizing said copolymer claim 37 , said polymeric solution and/or said risperidone or paliperidone prior to administration.46. The method of claim 45 , wherein said sterilizing comprises exposure to a dose of beta-irradiation in the range of 5-25 KGy; or wherein said sterilizing comprises filtering said polymeric solution.47. The method of claim 37 , wherein said injectable composition releases 0.5% wt up to 20% wt of its charge of risperidone or paliperidone within 24 hours after being placed in an aqueous environment.48. The method of claim 37 , wherein the drug has a particle size distribution selected from the group consisting ofa) not more than 10% of the total volume of the particles are smaller than 10 microns, and not more than 10% of the total volume of particles are greater than 225 microns;b) not more than 10% of the total volume of the particles is less than the range 1-10 μm, not more than 10% of the total volume of particles is greater than the range 225-400 μm, and the d0.5 of the size distribution is in the range of about 40-200 μm;c) expressed as volume, d0.9 is about 150 to about 400 μm, d0.5 is about 40 to about 200 μm and d0.1 is about 10 to about 60 μm;d) not more than 10% of the total volume of the particles is less than the range 0.1-10 μm, not more than the 10% of the total volume of particles is greater than the range 225-1000 μm, and the d0.5 of the size distribution is in the range of about 10-1000 μm;e) not more than 10% of the total volume of the particles is less than the range 0.5-10 μm, not more than the 10% of the total volume of particles is greater than the range 225-700 μm, and the d0.5 of the size distribution is in the range of about 20-700 μm;f) not more than 10% of the total volume of the particles is less than the range 1-10 μm, not more than the 10% of the total volume of particles is greater than the range 225-400 μm, and the d0.5 of the size distribution is in the range of about 40-200 μm;g) d0.1 of 27.49 microns, d0.5 of 79.9 microns, and d0.9 of 176.66 microns;h) d0.1 of 17.41 microns, d0.5 of 51.61 microns, and d0.9 of 175.32 microns; andi) d0.1 of ≤10 microns, d0.5 of 40-130 microns, and d0.9 of >225 microns.49. The method of claim 37 , wherein said monomer ratio ranges from 48:52 to 52:48.